drug · small molecule

OTEZLA

updated 3mo ago

by $AMGN AMGEN INC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 23 investigational indications.

targets

Phosphodiesterase 4

all catalysts(0)

nothing on the calendar yet

Trials studying OTEZLA

phase3A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasiscompletedn=912
phase3A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001completedn=862
phase3HPP737 in Adult Patients With Plaque Psoriasiscompletedn=607
phase3Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritisrecruitingn=60
phase3A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasisactive not recruitingn=17
phase3A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)completedn=203
phase3A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasiscompletedn=160
phase3Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Diseaserecruitingn=60

more trials →

News(6)

MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
fiercebiotech · 4d ago
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.
biospace · 11d ago
InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test
InnoCare Pharma announced Monday that its oral tyrosine kinase 2 (TYK2) inhibitor fadeucravacitinib met the primary endpoint in a phase 3 trial of adults with moderate-to-severe plaque psoriasis.
fiercebiotech · 18d ago
Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 update
Takeda has unveiled more data from its phase 3 trials of zasocitinib, demonstrating that the once-daily pill was able to clear or almost clear scalp psoriasis in 75% of patients.
fiercebiotech · 29d ago
cAMPfield lands $180M to build gut disease drug
The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
biopharma_dive · 1mo ago
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
biopharma_dive · 2mo ago

brand

OTEZLA

trade names

Apremilast accord, Otezla

generic

APREMILAST

MOA

12.1 Mechanism of Action Apremilast is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. The specific mechanism(s) by which apremilast exerts its therapeutic action is not well defined.

indication

1 INDICATIONS AND USAGE OTEZLA/OTEZLA XR, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with: Active psoriatic arthritis ( 1.1 ) Plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Oral ulcers associated with Behçet's Disease ( 1.3 ) Pediatric patients 6 years of age and older with: Active psoriatic arthritis ( 1.1 ) Moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) In the pediatric population, OTEZLA is indicated for patients weighing at least 20 kg, and OTEZLA XR is indicated for patients weighing at least 50 kg. 1.1 Psoriatic Arthritis OTEZLA is indicated for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 20 kg with active psoriatic arthritis. OTEZLA XR is indicated for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 50 kg with active psoriatic arthritis. 1.2 Plaque Psoriasis OTEZLA/OTEZLA XR is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. OTEZLA is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. OTEZLA XR is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 50 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 1.3 Oral Ulcers Associated with Behçet's Disease OTEZLA/OTEZLA XR is indicated for the treatment of adult patients with oral ulcers associated with Behçet's Disease.

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 27m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

OTEZLA

updated 3mo ago

by $AMGN AMGEN INC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 23 investigational indications.

targets

Phosphodiesterase 4

all catalysts(0)

nothing on the calendar yet

Trials studying OTEZLA

phase3A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasiscompletedn=912
phase3A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001completedn=862
phase3HPP737 in Adult Patients With Plaque Psoriasiscompletedn=607
phase3Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritisrecruitingn=60
phase3A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasisactive not recruitingn=17
phase3A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)completedn=203
phase3A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasiscompletedn=160
phase3Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Diseaserecruitingn=60

more trials →

News(6)

MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
fiercebiotech · 4d ago
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.
biospace · 11d ago
InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test
InnoCare Pharma announced Monday that its oral tyrosine kinase 2 (TYK2) inhibitor fadeucravacitinib met the primary endpoint in a phase 3 trial of adults with moderate-to-severe plaque psoriasis.
fiercebiotech · 18d ago
Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 update
Takeda has unveiled more data from its phase 3 trials of zasocitinib, demonstrating that the once-daily pill was able to clear or almost clear scalp psoriasis in 75% of patients.
fiercebiotech · 29d ago
cAMPfield lands $180M to build gut disease drug
The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
biopharma_dive · 1mo ago
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
biopharma_dive · 2mo ago

brand

OTEZLA

trade names

Apremilast accord, Otezla

generic

APREMILAST

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 27m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

OTEZLA

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying OTEZLA

News(6)

Report a data issue

comments(0)

OTEZLA

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying OTEZLA

News(6)

Report a data issue

comments(0)